Supernus Pharmaceuticals Inc (SUPN) US$0.001

Sell:$33.50Buy:$56.66Price increased$0.17 (0.34%)

NASDAQ:Price decreased0.89%
Market closed |
Prices delayed by at least 15 minutes
Sell:$33.50
Buy:$56.66
Change:Price increased$0.17 (0.34%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$33.50
Buy:$56.66
Change:Price increased$0.17 (0.34%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. It is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.

Key people

Charles W. Newhall
Independent Chairman of the Board
Bethany L. Sensenig
Independent Director
Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
Timothy C. Dec
Chief Financial Officer, Senior Vice President
Frank Mottola
Chief Operating Officer, Chief Technology Officer
Padmanabh P. Bhatt
Senior Vice President - Intellectual Property, Chief Scientific Officer
Jonathan Rubin
Senior Vice President, Chief Medical Officer - Research and Development
Carrolee Barlow
Independent Director
Georges Gemayel
Independent Director
Frederick M. Hudson
Independent Director
Click to see more

Key facts

  • Shares in issue
    57.58m
  • EPIC
    SUPN
  • ISIN
    US8684591089
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $2.83bn
  • Employees
    778
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.